Tumor BiologyPub Date : 2026-01-01Epub Date: 2026-08-16DOI: 10.1177/14230380261472771
Jong Do Seo, Huub H Van Rossum, Yeo-Min Yun
{"title":"Beyond proficiency testing: Leveraging commutable External Quality Assessment data to harmonize tumor markers and refine medical decision points.","authors":"Jong Do Seo, Huub H Van Rossum, Yeo-Min Yun","doi":"10.1177/14230380261472771","DOIUrl":"https://doi.org/10.1177/14230380261472771","url":null,"abstract":"<p><p>BackgroundSerum tumor markers such as carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and prostate-specific antigen (PSA) are crucial to clinical decision-making based on defined medical thresholds. However, significant inter-method variability and lack of harmonization limit result comparability and hinder consistent application of international guidelines.ObjectiveThis letter proposes an expanded role for External Quality Assessment (EQA) programs as active drivers of assay harmonization beyond conventional proficiency testing.MethodsThis proposal draws on recent studies evaluating the commutability of frozen human serum pools (FSPs) from the Korean Association of External Quality Assessment Service (KEQAS) and findings from EQA-based harmonization simulations. It demonstrated that harmonization of tumor markers such as CA 15-3 and CEA, is achievable.ResultsKEQAS FSPs demonstrated commutability for AFP, CEA, and total PSA across major diagnostic platforms. Simulation results indicated that \"in silico\" recalibration substantially reduced inter-method variability; for example, the bias range for CA 15-3 was reduced from [-29.28%, 9.86%] to [-0.09%, 0.12%], and recalibrating outlier methods for CEA improved the alignment also.ConclusionsEQA programs can serve as practical harmonization hubs by leveraging commutable materials and implementing EQA-driven recalibration. Such approaches can help that medical decision points, retain consistent clinical significance across diverse analytical systems.</p>","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"48 ","pages":"14230380261472771"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2026-01-01Epub Date: 2026-05-22DOI: 10.1177/14230380261450003
{"title":"Retraction: \"MicroRNA-337 inhibits cell proliferation and invasion of cervical cancer through directly targeting specificity protein 1\".","authors":"","doi":"10.1177/14230380261450003","DOIUrl":"https://doi.org/10.1177/14230380261450003","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"48 ","pages":"14230380261450003"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147989367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2026-01-01Epub Date: 2026-10-15DOI: 10.1177/14230380261493875
Melanie Moore, Katherine Partridge, Dina Vara, Leandro Lo Cascio, Ben Cowper
{"title":"WHO International Standards for tumour markers: Development, characterisation and future perspectives.","authors":"Melanie Moore, Katherine Partridge, Dina Vara, Leandro Lo Cascio, Ben Cowper","doi":"10.1177/14230380261493875","DOIUrl":"https://doi.org/10.1177/14230380261493875","url":null,"abstract":"<p><p>BackgroundMeasurement of the circulating protein-based tumour markers by immunoassay is used in the routine clinical care of cancer patients, from aiding diagnosis to monitoring disease progression, response to therapy and detecting recurrence. The standardisation of these immunoassays is of critical importance, where inter-method variability and a lack of harmonisation can impact the comparability of results and affect clinical utility. World Health Organisation (WHO) International Standards (IS) are available for many of these protein tumour markers.ObjectiveTo provide an overview of how these WHO IS are prepared, characterised and established, and introduce the IS that are available for the calibration of tumour marker immunoassays.Results and conclusionAlthough WHO IS are available for many protein tumour markers, there remains a need for improvement in the harmonisation of some of these assays to enable more widespread and optimum utilisation in clinical practice. It will remain important to maintain these WHO International Standards, to achieve harmonisation through consistent global calibration of these assays, in addition to supporting the development of new technologies as they arise.</p>","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"48 ","pages":"14230380261493875"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2026-01-01Epub Date: 2026-10-21DOI: 10.1177/14230380261497644
Aleksi Rytkönen, Auli Suominen, Antti Mäkitie, Caj Haglund, Hanna K Laine, Jaana Hagström
{"title":"Prognostic value of E-cadherin, syndecan-2, and cyclin D1 immunohistochemistry in minor salivary gland adenoid cystic carcinoma: A cohort study.","authors":"Aleksi Rytkönen, Auli Suominen, Antti Mäkitie, Caj Haglund, Hanna K Laine, Jaana Hagström","doi":"10.1177/14230380261497644","DOIUrl":"https://doi.org/10.1177/14230380261497644","url":null,"abstract":"<p><p>BackgroundAdenoid cystic carcinoma (ACC) of the salivary glands has a poor long-term prognosis. Independent prognostic factors of ACC include histological and clinicopathological features, while a validated gold-standard prognostic immunohistochemical markers are still lacking. Functions of cell adhesion molecule E-cadherin which maintain epithelial integrity, and cell cycle and function regulators nuclear protein Cyclin D1 and transmembrane heparan sulfate proteoglycan syndecan-2 in ACC have not been studied.ObjectiveThe aim of this study was to investigate the immunohistochemical expression of E-cadherin, syndecan-2, and cyclin D1 in ACC of the minor salivary glands. Our objective was to evaluate the prognostic relevance of these markers in relation to disease progression and patient outcomes.MethodsThis retrospective study included 46 patients with minor salivary gland ACC treated at the Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital, Finland, between 1974 and 2012. Formalin-fixed paraffin-embedded tumor tissue samples were used for immunohistochemical analysis. Staining intensity was scored and associated with clinicopathological parameters and survival data.ResultsImmunopositivity varied among tumors, sometimes exhibiting heterogeneous expression within the same tumor. We found moderate to high E-cadherin expression to significantly associate with improved overall (<i>p</i> = 0,024) and disease-specific survival (<i>p</i> = 0.005). Additionally in multivariate analysis, moderate to high E-cadherin associated with better disease-specific survival with hazard ratio of 0.219 (95% CI 0.065-0.734, <i>p</i> = 0.014). Notably, all four patients with neck recurrences demonstrated low syndecan-2 positivity (<i>p</i> = 0.023). Cyclin D1 did not associate significantly with survival.ConclusionsIn conclusion, all the studied markers were expressed in the minor salivary gland ACC. E-cadherin showed potentiality as a prognostic immunohistochemical biomarker for survival analysis. Low syndecan-2 expression may be indicative for regional recurrence. Validation in larger multicenter cohorts is warranted to confirm these observations.</p>","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"48 ","pages":"14230380261497644"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149239571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2026-01-01Epub Date: 2026-11-02DOI: 10.1177/14230380261504696
Linmei Zhong, Yi Yao, Xu Qian
{"title":"Harmonization and standardization of tumor markers and liquid biopsies in China: A short perspective.","authors":"Linmei Zhong, Yi Yao, Xu Qian","doi":"10.1177/14230380261504696","DOIUrl":"https://doi.org/10.1177/14230380261504696","url":null,"abstract":"<p><p>Circulating tumor markers such as serum carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and carbohydrate antigen (CA) 15-3 are widely used. In recent years, liquid biopsies, including circulating tumor DNA and tumor mutational burden, have been developed. In this review, we describe the status of harmonization and standardization of tumor markers in clinical practice in China, based on a systematic literature search of the CNKI and PubMed databases. Substantial inter-laboratory variability in measurement results persists. Participation in national external quality assessment (EQA) schemes and proficiency testing (PT) has successfully mitigated result discrepancies across different instruments and laboratory procedures during the last decades. Further development and refinement of standardization and harmonization approaches for liquid biopsies remain an unmet need.</p>","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"48 ","pages":"14230380261504696"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2026-01-01Epub Date: 2026-07-12DOI: 10.1177/14230380261466593
Xavier Filella
{"title":"Standardization of prostate-specific antigen assays: Impact on reference intervals and clinical decision thresholds.","authors":"Xavier Filella","doi":"10.1177/14230380261466593","DOIUrl":"https://doi.org/10.1177/14230380261466593","url":null,"abstract":"<p><p>BackgroundProstate-specific antigen (PSA) remains the most widely used biomarker for prostate cancer screening, diagnosis, and monitoring. However, despite decades of standardization efforts, significant inter-assay variability persists, with important consequences for clinical interpretation and decision-making.ObjectiveThis review aims to evaluate the impact of PSA calibration and harmonization on reference intervals, clinical thresholds, and population-based screening strategies in contemporary clinical practice.MethodsA literature-based analysis was conducted, examining studies on PSA assay standardization, analytical variability, and evidence from population screening trials, including considerations from a Health Technology Assessment perspective.ResultsThe introduction of the World Health Organization (WHO) International Standard 96/670 improved comparability among PSA assays, yet clinically relevant differences between platforms remain. This variability is driven by differences in calibration, antibody specificity, epitope recognition, and assay design. As a result, PSA values are not directly interchangeable across assays, and assay-specific cut-offs may be necessary to maintain diagnostic performance. Historically established thresholds, such as the 4 μg/L cut-off and the \"gray zone,\" were derived using specific assay systems and are influenced by methodological limitations. PSA-derived metrics, including PSA density, improve specificity but are still affected by inter-assay variability. Evidence from large randomized trials supports a PSA cut-off of 3.0 μg/L for population screening, showing a reduction in prostate cancer mortality when implemented within structured programs; however, this threshold is intrinsically linked to the analytical characteristics of the assays used. PSA also shows relevant intra-individual biological variability beyond analytical variation, with within-subject variation of 6-13%.ConclusionsPSA standardization remains incomplete, and inter-assay variability and biological variability continues to influence clinical interpretation. The implementation of PSA-based screening programs must explicitly consider the assay-specific nature of evidence-derived thresholds, including the 3.0 μg/L cut-off, to ensure consistent, effective, and safe clinical decision-making.</p>","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"48 ","pages":"14230380261466593"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2026-01-01Epub Date: 2026-01-02DOI: 10.1177/14230380251410478
Kateryna Maslova, Magdalena Chechlinska, Irmina Maria Michalek, Lukasz Taraszkiewicz, Paulina Kober, Inga Trulson, Karolina Worf, Sophie Gabriel, Laura Knoblauch, Fiona Campbell, Ian A Cree, Stefan Holdenrieder, Magdalena Kowalewska
{"title":"Tumour markers and evidence-based pathology.","authors":"Kateryna Maslova, Magdalena Chechlinska, Irmina Maria Michalek, Lukasz Taraszkiewicz, Paulina Kober, Inga Trulson, Karolina Worf, Sophie Gabriel, Laura Knoblauch, Fiona Campbell, Ian A Cree, Stefan Holdenrieder, Magdalena Kowalewska","doi":"10.1177/14230380251410478","DOIUrl":"10.1177/14230380251410478","url":null,"abstract":"<p><p>BackgroundTumour biomarkers have become increasingly important in oncology, shaping cancer diagnostics, classification, and patient management. Despite their potential, the use of cancer biomarkers in clinical settings remains limited.ObjectiveThis paper aims to outline biomarker development, from classical, serum protein markers to emerging tumour biomarkers, including meta-biomarkers, to show their diversity and point out the challenges in their development, reporting, and implementation in clinical practice as well as their relevance in evidence-based pathology and cancer classification.MethodsA literature-based analysis, incorporating insights from our ongoing research, is presented.ResultsAlthough numerous potential biomarkers, biomarker signatures, and meta-biomarkers, are being discovered, existing innovations are often not supported by sufficiently rigorous research methodologies and standardised reporting practices to enable their translation into clinical practice.ConclusionsTo ensure that biomarker discoveries are both scientifically sound and clinically useful, improved research and validation methods, along with adherence to established reporting standards, are essential. We propose the use of the Hierarchy of Evidence for Tumour Pathology as a framework to evaluate and map existing evidence and identify knowledge gaps and research priorities.</p>","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"48 ","pages":"14230380251410478"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145893293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2026-01-01Epub Date: 2026-07-01DOI: 10.1177/14230380261461490
Sara A Al-Shun, Magdy M Youssef, Farid A Badria
{"title":"Digitoxin as a novel synergistic partner of cisplatin in triple-negative breast cancer (TNBC) cells.","authors":"Sara A Al-Shun, Magdy M Youssef, Farid A Badria","doi":"10.1177/14230380261461490","DOIUrl":"10.1177/14230380261461490","url":null,"abstract":"<p><p>BackgroundTriple-negative breast cancer (TNBC) remains clinically challenging due to its aggressive nature, high recurrence rate, and lack of targeted therapies. To address these limitations, combination chemotherapies that synergistically enhance antitumor efficacy while permitting dose reduction and supporting dose-sparing strategies are urgently needed. Cisplatin has a broad spectrum of anticancer activity. However, its resistance and dose-limiting toxicities constrain clinical benefit. Digitoxin is a cardiac glycoside that has anticancer activity.ObjectiveWe aimed to assess the nature of interaction between digitoxin and cisplatin in TNBC cells, define the most synergistic area (MSA), and estimate dose-sparing potential.MethodsWe profiled digitoxin-cisplatin effects in MDA-MB-231 TNBC cell line by checkerboard and fixed-ratio designs, quantifying interaction with Chou-Talalay combination index/dose-reduction index by CompuSyn, and multiple matrix models by SynergyFinder.ResultsThe CI analysis demonstrated synergy across all tested ratios, with the strongest synergistic interaction at a digitoxin/cisplatin ratio of 1:200 (CI = 0.30 at ED<sub>97</sub>). Dose-reduction analysis showed up to 27-fold cisplatin sparing (ratio 1:25, ED<sub>97</sub>). Matrix-based models confirmed synergy (Bliss 6.9, Loewe 18.6, ZIP 7.1, and HSA 14), converging on MSA at 31.25 nM digitoxin and 6.25 µM cisplatin.ConclusionOur results highlight a robust synergistic interaction between digitoxin and cisplatin in MDA-MB-231 cells with a dosing window that maximizes cytotoxic effect while potentially reducing cisplatin exposure.</p>","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"48 ","pages":"14230380261461490"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2026-01-01Epub Date: 2026-05-22DOI: 10.1177/14230380251408221
{"title":"Retraction: \"LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205\".","authors":"","doi":"10.1177/14230380251408221","DOIUrl":"https://doi.org/10.1177/14230380251408221","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"48 ","pages":"14230380251408221"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147989305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor BiologyPub Date : 2026-01-01Epub Date: 2026-11-04DOI: 10.1177/14230380261504697
Huub H van Rossum, Theodora C Linders, Henk Huijgen, Ruben E A Musson, Ayşe Y Demir, Michael J Duffy, Melanie Moore
{"title":"Verification of a previously obtained EQA based MUC1/CA15-3 harmonisation procedure.","authors":"Huub H van Rossum, Theodora C Linders, Henk Huijgen, Ruben E A Musson, Ayşe Y Demir, Michael J Duffy, Melanie Moore","doi":"10.1177/14230380261504697","DOIUrl":"https://doi.org/10.1177/14230380261504697","url":null,"abstract":"<p><p>ObjectivesMUC1/CA 15-3 is the most widely used circulating marker for monitoring treatment in patients with advanced breast cancer. Previous studies demonstrated that MUC1/CA 15-3 tests are insufficiently harmonised and an EQA-based harmonisation procedure has been developed. This study aims to validate the obtained MUC1/CA 15-3 harmonisation procedure and to explore the suitability of MUC1/CA 15-3 materials as a base for developing future MUC1/CA 15-3 reference materials.MethodsSera from 45 patients were obtained and five additional samples were prepared from commercial MUC1/CA 15-3 materials. All samples were analyzed by measurement procedures of Abbott Alinity, Beckman DxI, Roche Cobas and Siemens Atellica. Data analysis included application of the previously obtained MUC1/CA 15-3 harmonisation procedure that required recalibration of Beckman DxI only, pre-and post-harmonisation Passing-Bablok regression, Spearman correlation coefficient and Bland-Altman difference analyses. Suitability of the MUC1/CA 15-3 materials as basis of future standards was also investigated.ResultsThe slopes obtained from the regression analysis of individual MUC1/CA15-3 assays ranged from 0.598 to 1.96 pre-harmonisation and 0.8448 to 1.150 post-harmonisation. The mean difference of individual measurement procedures with the consensus mean improved from -26.65% to 22.83% before harmonisation to -12.78% to 10.95% after harmonisation. The difference between the MUC1/CA 15-3 spiked materials and the patient sample mean differences were ≤10,1% and fell within the 95% limits of agreement.ConclusionsThe EQA-based mathematical harmonisation procedure for MUC1/CA 15-3 resulted in improved MUC1/CA 15-3 harmonisation with real-world clinical samples. The MUC1/CA 15-3 materials provided a suitable base for further exploration as reference materials.</p>","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":"48 ","pages":"14230380261504697"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}